FDG PET/CT in children and adolescents with lymphoma

Pediatric Radiology

Volumn 43, Issue 4, 2013, Pages 406-417

  Kluge, Regine ^a   Kurch, Lars ^a   Montravers, Françoise ^b   Mauz Körholz, Christine ^c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b HÔPITAL TENON   (France)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

FDG; Hodgkin lymphoma; Non Hodgkin lymphoma; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BURKITT LYMPHOMA; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; LYMPHOBLASTOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; INFANT; INFANT, NEWBORN; LYMPHOMA; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84876237944     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-012-2559-z     Document Type: Conference Paper

References (87)

1. Kaatsch P (2010) Epidemiology of childhood cancer. Cancer Treat Rev 36:277-285
2. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392
3. Hansmann ML, Willenbrock K (2002) Die WHO-Klassifikation des Hodgkin-Lymphoms und ihre molekulargenetische Relevanz. Der Pathologe 29:1393-1398
4. Klapper W, Oschlies I (2012) Specifics of histopathological and genetical diagnosis and classification of lymphomas in children and adolescents. Klin Pädiatr 224:183-190
5. Sandoval C, Venkateswaran L, Billups C et al (2002) Lymphocyte- predominant Hodgkin disease in children. J Pediatr Hematol Oncol 24:269-273
6. Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al (2003) Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection - a study of the French Society of Pediatric Oncology. J Clin Oncol 21:2948-2952
7. Hall GW, Katzilakis N, Pinkerton CR et al (2007) Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol 138:761-768
8. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al (2007) Resection alone in 58 children with limited stage lymphocyte-predominant Hodgkin lymphoma - experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer 110:179-185
9. Mauz-Körholz C, Hasenclever D, Dörffel W et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28:3680-3686
10. Bhatia S, Yasui Y, Robison LL et al (2003) High risk of subsequent neoplasm continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 21:4386-4394
11. Prasad PK, Signorello LB, Friedman DL et al (2012) Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer 58:421-427
12. Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac Disease following treatment of Hodkgin's disease in children and adolescents. J Clin Oncol 11:1208-1215
13. Illes A, Biro E, Miltenyi Z et al (2003) Hypothyroidism and thyroiditis after therapy for Hodgkin's disease. Acta Haematol 109:11-17
14. Körholz D, Claviez A, Hasenclever D et al (2004) The concept of the GPOH-HD-2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH Studies. Klin Pädiatr 216:150-156
15. Schellong G (1996) Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 9:619-634
16. Dörffel W, Lüders H, Rühl U et al (2003) Preliminary results of multicenter trial GPOH-HD-95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Pädiatr 215:139-145
17. Reiter A, Schrappe M, Ludwig WD et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416-421
18. Wossmann W, Seidemann K, Mann G et al (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasm: a report of the BFM Group Study NHL-BFM95. Blood 105:948-958
19. Brugieres L, Minard V, Patte C et al (2012) Lymphoma in children and adolescents. Rev Prat 62:453-458
20. Reiter A, Ferrando AA (2009) Malignant lymphomas and lymphadenopathies. In: Orkin SH et al (eds) Oncology of infancy and childhood. Saunders, Philadelphia, pp 417-505
21. Iversen OH, Iversen U, Ziegler JL et al (1974) Cell kinetics in Burkitt lymphoma. Eur J Cancer 10:155-163
22. Molyneux EM, Rochford R, Griffin B et al (2012) Burkitt's lymphoma. Lancet 379:1234-1244
23. Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430
24. Abramson SJ, Price AC (2008) Imaging of pediatric lymphomas. Radiol Clin North Am 46:313-338
25. Cairo MS, Raetz E, Lim MS et al (2005) Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 45:753-769
26. Pinkerton R (2005) Continuing challenges in childhood non-Hodgkin's. Br J Haematol 130:480-488
27. Tsukamoto N, Kojima M, Hasegawa M et al (2007) The usefulness of 18F-fluorodeoxyglucose positron emission tomography 18F-FDG-PET and a comparison of 18F-FDG-PET with 67 gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659
28. Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876
29. Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897-903
30. Weiler-Sagie M, Bushelev O, Epelbaum R et al (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25-30
31. 18F-fluorodeoxyglucose compared to standard procedure for staging patients with Hodgkin's disease. Haematologica 86:266-273
32. Hutchings M, Loft A, Hansen M et al (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24:146-150
33. 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 33:1025-1031
34. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging 38:274-284
35. Hutchings M, Loft A, Hansen M et al (2006) Positron emission tomography with and without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489
36. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072-1074
37. Pelosi E, Penna D, Deandreis D et al (2008) FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 52:9-16
38. Moulin-Romsee, Hindie E, Cuenca X et al (2010) 18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095-1105
39. Chen G, Chen W, Chamroonrat W et al (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patient. Eur J Nucl Med Mol Imaging 38:1469-1476
40. 18F] fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 29:3523-3528
41. Weihrauch MR, Bischoff RD, Dietlein M et al (2002) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81:20-25
42. 18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med 29:1155-1165
43. Hermann S, Wormanns D, Pixberg M et al (2005) Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 44:1-7
44. 18F-FDG-PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32:31-38
45. Munker R, Glass J, Griffeth LK et al (2004) Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15:1699-1704
46. Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854
47. Girinsky T, Ghalibafian M, Bonniaud G et al (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85:178-186
48. Quarles van Ufford H, Hoekstra O, de Haas M et al (2010) On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol 12:225-232
49. Muslimani AA, Faraq HL, Francis S et al (2008) The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol 31:409-412
50. Montravers F, Landman-Parker J, Kerrou K et al (2006) Impact of FDG PET on the management of childhood non-Hodgkin lymphoma: a five-year experience. J Nucl Med 47:87P
51. Toma P, Granata C, Rossi A et al (2007) Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics 27:1335-1354
52. 67 Ga scintigraphy in the posttherapy evaluation of malignant lymphoma. Radiographics 30:939-957
53. Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475-481
54. 18F- fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol 22:705-711
55. 18F-FDG and PET/CT in Burkitt's lymphoma. Eur J Radiol 75:68-73
56. 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 45:1838-1842
57. Aldinucci D, Gloghini A, Pinto A et al (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221:248-263
58. Meignan M (2010) Interim PET in lymphoma: step towards standardization. Eur J Nucl Med Mol Imaging 37:1821-1823
59. Gallamini A, Fiore A, Sorasio R et al (2009) Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 50:1761-1764
60. 18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 27:4385-4391
61. Kostakoglu L, Coleman M, Leonard JP et al (2002) PET predicts prognosis after 1cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027
62. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59
63. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752
64. Kluge R, Körholz D (2011) Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Pädiatr 223:315-319
65. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578
66. Körholz D, Kluge R, Wickmann L et al (2003) Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie 26:489-493
67. Gallamini A, Patti C, Viviani S et al (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol 152:551-560
68. Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50:1257-1260
69. Barrington SF, Qian W, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentric trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824-1833
70. Horning SJ, Juweid ME, Schöder H et al (2010) Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 115:775-777
71. Kurch L, Hasenclever D, Elsner A et al (2012) Semiautomatic approach for discrimination between adequate and inadequate early response in FDG-PET/CT of paediatric Hodgkin lymphoma (PHL) patients. J Nucl Med 53:155
72. Wahl RL, Jacene H, Kasamon Y et al (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 5:122-150
73. Casasnovas R, Meignan M, Berriolo-Riedinger A et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43
74. Moskowitz C (2012) Diffuse large B cell lymphoma: how can we cure more patients in 2012? Best Pract Res Clin Haematol 25:41-47
75. Dührsen U, Hüttmann A, Jöckel KH et al (2009) Positron emission tomography guided therapy of aggressive non-Hodgkin lymphoma - the PETAL trial. Leuk Lymphoma 50:1757-1760
76. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632
77. Pregno P, Chiappella A, Bello M et al (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119:2066-2073
78. 18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30:184-190
79. Amthauer H, Furth C, Denecke T et al (2005) FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Klin Pädiatr 217:327-333
80. 18F fluorodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 48:699-707
81. Riad R, Omar W, Sidhom I et al (2010) False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma. Nucl Med Commun 31:232-238
82. Filmont J, Gisselbrecht C, Cuenca X et al (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110:1361-1369
83. 18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16:260-267
84. Spaepen K, Stroobants S, Dupont P et al (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102:53-59
85. Qiao W, Zhao J, Wang C et al (2010) Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Hematology 15:21-27
86. Jabbour E, Hosing C, Avers G et al (2007) Pretransplant positive positron emission tomography/gallium scan predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109:2481-2489
87. Moskowitz AJ, Yahalom J, Kewalramani T et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:4934-4937